ShantaQ's beauty hack claim needs context we don't have
Quick answer
GLP-1 receptor agonists including semaglutide and tirzepatide produce significant fat loss that can reduce facial volume, a phenomenon increasingly called 'Ozempic face' in popular media. Microcurrent home devices have limited but real evidence for improving superficial skin tone and muscle firmness, though they do not address the subcutaneous fat redistribution that drives GLP-1-related facial changes. Patients concerned about facial volume loss while on GLP-1 therapy should discuss the rate of weight loss, protein intake, and potential dermatologic interventions with their prescriber.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @heyshantaqtv actually say?
She acknowledged her own facial volume loss directly: "I have a Ozempic face. Of course I do. I've lost a lot of weight in a short amount of time." She then credited a MediCUBE device, used "two to three minutes, three times a day," with reducing smile lines and contouring her face. She called Korean skincare products "scientific and proven" and implied the $299 device is worth it for "good skin." To her credit, she wasn't claiming the device reverses GLP-1-related fat loss. She was claiming it helps contour and improve skin appearance after that loss, which is a more modest claim than most beauty influencers make. That distinction matters here.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For ShantaQ's beauty hack claim needs context we don't have, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
ShantaQ's beauty hack claim needs context we don't have should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
GLP-1 receptor agonists including semaglutide and tirzepatide produce significant fat loss that can reduce facial volume, a phenomenon increasingly called 'Ozempic face' in popular media.
FormBlends verdict
GLP-1 receptor agonists including semaglutide and tirzepatide produce significant fat loss that can reduce facial volume, a phenomenon increasingly called 'Ozempic face' in popular media. Microcurrent home devices have limited but real evidence for improving superficial skin tone and muscle firmness, though they do not address the subcutaneous fat redistribution that drives GLP-1-related facial changes. Patients concerned about facial volume loss while on GLP-1 therapy should discuss the rate of weight loss, protein intake, and potential dermatologic interventions with their prescriber.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists including semaglutide and tirzepatide produce significant fat loss that can reduce facial volume, a phenomenon increasingly called 'Ozempic face' in popular media. Microcurrent home devices have limited but real evidence for improving superficial skin tone and muscle firmness, though they do not address the subcutaneous fat redistribution that drives GLP-1-related facial changes. Patients concerned about facial volume loss while on GLP-1 therapy should discuss the rate of weight loss, protein intake, and potential dermatologic interventions with their prescriber.
- GLP-1-related facial volume loss is real: rapid weight loss reduces subcutaneous facial fat, which is distinct from skin aging and requires different interventions than topical or device-based skincare.
- Microcurrent devices have peer-reviewed support for mild skin tightening (Franks et al., 2019), but home devices deliver lower current than clinical studies used, so results are likely more modest.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- GLP-1-related facial volume loss is real: rapid weight loss reduces subcutaneous facial fat, which is distinct from skin aging and requires different interventions than topical or device-based skincare.
- Microcurrent devices have peer-reviewed support for mild skin tightening (Franks et al., 2019), but home devices deliver lower current than clinical studies used, so results are likely more modest.
- Jacobs et al. (2023) found that the faster the weight loss, the more pronounced the facial aging markers, suggesting that slowing loss rate with your prescriber may reduce the effect.
- She used at least two MediCUBE devices plus 'a whole plethora of other products,' meaning any observed skin improvement cannot be attributed to one product with confidence.
- No topical product or consumer microcurrent device restores subcutaneous fat volume. For significant volume loss, injectable fillers remain the only intervention with strong clinical evidence.
- The $299 price point for a home microcurrent device is within the range sold by legitimate brands, but the FDA does not independently verify efficacy claims for most at-home beauty devices before sale.
- If you are on semaglutide or tirzepatide and concerned about facial changes, ask your prescriber about adjusting your rate of loss and consult a board-certified dermatologist before investing in device-based solutions.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
ShantaQuilette · TikTok creator
163.6K views on this video
Listen, try it a money back guarantee. #beauty #beautyhacks #beaitymode #beatytips
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by ShantaQuilette, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.